{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:42:54Z","timestamp":1794084174988,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12032-018-1140-5","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T04:18:51Z","timestamp":1524716331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors"],"prefix":"10.1007","volume":"35","author":[{"given":"Yuki","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-3000","authenticated-orcid":false,"given":"Takuya","family":"Sadahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoo","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyohiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutomo","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"1140_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1200\/JCO.1995.13.2.470","volume":"13","author":"P Loehrer","year":"1995","unstructured":"Loehrer P, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:470\u20136.","journal-title":"J Clin Oncol"},{"key":"1140_CR2","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1200\/JCO.1997.15.5.1837","volume":"15","author":"R Wit de","year":"1997","unstructured":"de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15:1837\u201343.","journal-title":"J Clin Oncol"},{"key":"1140_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","volume":"15","author":"International Germ Cell Cancer Collaborative Group","year":"1997","unstructured":"International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997; 15: 594\u2013603.","journal-title":"J Clin Oncol"},{"key":"1140_CR4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/1097-0142(197304)31:4<903::AID-CNCR2820310422>3.0.CO;2-N","volume":"31","author":"RH Blum","year":"1973","unstructured":"Blum RH, Carter SK, Aqre K. A clinical review of bleomycin - a new antineoplastic agent. Cancer. 1973;31:903\u201314.","journal-title":"Cancer"},{"key":"1140_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/annonc\/mdg020","volume":"14","author":"JM O\u2019Sullivan","year":"2003","unstructured":"O\u2019Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:91\u20136.","journal-title":"Ann Oncol"},{"key":"1140_CR6","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1200\/JCO.1993.11.7.1300","volume":"11","author":"JA Levi","year":"1993","unstructured":"Levi JA, Raghavan D, Thompson D, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol. 1993;11:1300\u20135.","journal-title":"J Clin Oncol"},{"key":"1140_CR7","first-page":"1078","volume":"130","author":"P Barneveld Van","year":"1984","unstructured":"Van Barneveld P, Van der Mark DT, Sleijfer T, et al. Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis. 1984;130:1078\u201381.","journal-title":"Am Rev Respir Dis"},{"key":"1140_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/bjc.1998.628","volume":"78","author":"A Simpson","year":"1998","unstructured":"Simpson A, Paul J, Graham J, Kaye S. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer. 1998;78:1061\u20136.","journal-title":"Br J Cancer"},{"key":"1140_CR9","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1080\/10428194.2017.1307980","volume":"58","author":"HL Sun","year":"2017","unstructured":"Sun HL, Atenafu EG, Tsang R, et al. Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma. Leuk Lymphoma. 2017;58:2607\u201314.","journal-title":"Leuk Lymphoma"},{"key":"1140_CR10","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","volume":"23","author":"WG Martin","year":"2005","unstructured":"Martin WG, Ristow KM, Habermann TM, Colqan JP, Witziq TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:7614\u201320.","journal-title":"J Clin Oncol"},{"key":"1140_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.08.012","author":"EM Kwan","year":"2017","unstructured":"Kwan EM, Beck S, Amir E, et al. Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumors. Clin Genitourin Cancer. 2017. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2017.08.012\n                    \n                  .","journal-title":"Clin Genitourin Cancer"},{"key":"1140_CR12","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/jnci\/djq245","volume":"102","author":"PS Grimison","year":"2010","unstructured":"Grimison PS, Stockler MR, Thomson DB, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst. 2010;102:1253\u201362.","journal-title":"J Natl Cancer Inst"},{"key":"1140_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1140_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1378\/chest.111.3.657","volume":"111","author":"SB Saxman","year":"1997","unstructured":"Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with oud without granulocyte colony stimulating factor. Chest. 1997;111:657\u201360.","journal-title":"Chest"},{"key":"1140_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/imj.13158","volume":"46","author":"FT Roncolate","year":"2016","unstructured":"Roncolate FT, Chatfield M, Hougton B. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. Intern Med J. 2016;46:893\u20138.","journal-title":"Intern Med J"},{"key":"1140_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1200\/JCO.1990.8.5.779","volume":"8","author":"MJ McKeage","year":"1990","unstructured":"McKeage MJ, Evans BD, Atkinson C, Perez D, Forgeson GV, Dady P. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol. 1990;8:779\u201383.","journal-title":"J Clin Oncol"},{"key":"1140_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1445-5994.1985.tb04015.x","volume":"15","author":"MR Bell","year":"1985","unstructured":"Bell MR, Meredith DJ, Gill OG. Role of carbon monoxide diffusing capacity in the early detection of major bleomycin-induced pulmonary toxicity. Aust N Z J Med. 1985;15:235 \u2013 40.","journal-title":"Aust N Z J Med"},{"key":"1140_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1200\/JCO.1990.8.5.765","volume":"8","author":"RL Comis","year":"1990","unstructured":"Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol. 1990;8:765\u20137.","journal-title":"J Clin Oncol"},{"key":"1140_CR19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdx071","volume":"28","author":"J Shamash","year":"2017","unstructured":"Shamash J, Sarker SJ, Huddart R, et al. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Ann Oncol. 2017;28:1333\u20138.","journal-title":"Ann Oncol"},{"key":"1140_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mpo.2950120503","volume":"12","author":"AG Dalgleish","year":"1984","unstructured":"Dalgleish AG, Woods RL, Levi JA. Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol. 1984;12:313\u20137.","journal-title":"Med Pediatr Oncol"},{"key":"1140_CR21","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","volume":"23","author":"W Martin","year":"2005","unstructured":"Martin W, Ristow K, Habermann T, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:7614\u201320.","journal-title":"J Clin Oncol"},{"key":"1140_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1721","author":"C Lic","year":"2018","unstructured":"Lic C, Wang Q, Sun B, et al. Low BMI is correlated with increased TGF-\u03b2 and IL-10 mRNA levels in the peripheral blood of breast cancer patients. IUBMB Life. 2018. \n                    https:\/\/doi.org\/10.1002\/iub.1721\n                    \n                  .","journal-title":"IUBMB Life"},{"key":"1140_CR23","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","volume":"331","author":"WA Border","year":"1994","unstructured":"Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286\u201392.","journal-title":"N Engl J Med"},{"key":"1140_CR24","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1038\/ncomms3563","volume":"4","author":"H Sunaga","year":"2013","unstructured":"Sunaga H, Matsui H, Ueno M, et al. Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice. Nat Commun. 2013;4:2563. \n                    https:\/\/doi.org\/10.1038\/ncomms3563\n                    \n                  .","journal-title":"Nat Commun"},{"key":"1140_CR25","doi-asserted-by":"publisher","first-page":"1701785","DOI":"10.1183\/13993003.01785-2017","volume":"51","author":"H Coumou","year":"2018","unstructured":"Coumou H, Westerhof GA, de Nijs SB, Zwinderman AH, Bel EH. Predictors of accelerated decline in lung function in adult-onset asthma. Eur Respir J. 2018; 51:1701785. \n                    https:\/\/doi.org\/10.1183\/13993003.01785-2017\n                    \n                  .","journal-title":"Eur Respir J"},{"key":"1140_CR26","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/1097-0142(19851115)56:10<2411::AID-CNCR2820561012>3.0.CO;2-H","volume":"56","author":"G Pizzocaro","year":"1985","unstructured":"Pizzocaro G, Piva L, Salvioni R, Zanoni F, Milani A. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer. Cancer. 1985;56:2411\u20135.","journal-title":"Cancer"},{"key":"1140_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clgc.2016.08.021","volume":"15","author":"A Necchi","year":"2017","unstructured":"Necchi A, Miceli R, Oualla K, et al. Effect of bleomycin administration on the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy: a meta-analysis of randomized studies. Clin Cenitourin Cancer. 2017;15:213\u201320.","journal-title":"Clin Cenitourin Cancer"},{"key":"1140_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S1470-2045(04)01407-X","volume":"5","author":"G Jankilevich","year":"2004","unstructured":"Jankilevich G. BEP versus EP for treatment of metastatic germ-cell tumours. Lancet Oncol. 2004;5:146\u20137.","journal-title":"Lancet Oncol"},{"key":"1140_CR29","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(03)01279-8","volume":"4","author":"RH Jones","year":"2003","unstructured":"Jones RH, Vasey PA. Part II: testicular cancer\u2014management of advanced disease. Lancet Oncol. 2003;4:738\u201347.","journal-title":"Lancet Oncol"},{"key":"1140_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/annonc\/mdm062","volume":"18","author":"S Culine","year":"2007","unstructured":"Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18:917\u201324.","journal-title":"Ann Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1140-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1140-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T19:32:03Z","timestamp":1556220723000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1140-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1140-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,26]]},"assertion":[{"value":"23 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Okayama University Institutional Review Board prior to study initiation (Approval Number; 1803-013-005).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants and the dead patient\u2019s next of kin included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"80"}}